List of Triferic drug patents

Triferic is owned by Rockwell Medical Inc.

Triferic contains Ferric Pyrophosphate Citrate.

Triferic has a total of 2 drug patents out of which 0 drug patents have expired.

Triferic was authorised for market use on 25 April, 2016.

Triferic is available in for solution;intravenous dosage forms.

Triferic can be used as method of iron administration to treat patients in need of iron replacement.

The generics of Triferic are possible to be released after 17 April, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7857977 ROCKWELL MEDICAL INC Packaging of ferric pyrophosphate for dialysis
Sep, 2027

(4 years from now)

US7816404 ROCKWELL MEDICAL INC Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
Apr, 2029

(6 years from now)

Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Method of iron administration to treat patients in need of iron replacement

Dosage: FOR SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic